Usman Sumo Friend Tambunan, Rizky Archintya Rachmania, Arli Aditya Parikesit. In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1[J]. The Journal of Biomedical Research, 2015, 29(2): 150-159. DOI: 10.7555/JBR.29.20130024
Citation:
Usman Sumo Friend Tambunan, Rizky Archintya Rachmania, Arli Aditya Parikesit. In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1[J]. The Journal of Biomedical Research, 2015, 29(2): 150-159. DOI: 10.7555/JBR.29.20130024
Usman Sumo Friend Tambunan, Rizky Archintya Rachmania, Arli Aditya Parikesit. In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1[J]. The Journal of Biomedical Research, 2015, 29(2): 150-159. DOI: 10.7555/JBR.29.20130024
Citation:
Usman Sumo Friend Tambunan, Rizky Archintya Rachmania, Arli Aditya Parikesit. In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1[J]. The Journal of Biomedical Research, 2015, 29(2): 150-159. DOI: 10.7555/JBR.29.20130024
Bioinformatics Research Group, Department of Chemistry, Faculty of Mathematics and Natural Science, University of Indonesia, Depok Campus, Depok 16424, Indonesia
This research focused on the modification of the functional groups of oseltamivir as neuraminidase inhibitor against influenza A virus subtype H1N1. Interactions of three of the best ligands were evaluated in the hydrated state using molecular dynamics simulation at two different temperatures. The docking result showed that AD3BF2D ligand (N-[(1S,6R)-5-amino-5-{[(2R,3S,4S)-3,4-dihydroxy-4-(hydroxymethyl) tetrahydrofuran-2- yl]oxy}-4-formylcyclohex-3-en-1-yl]acetamide-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate) had better binding energy values than standard oseltamivir. AD3BF2D had several interactions, including hydrogen bonds, with the residues in the catalytic site of neuraminidase as identified by molecular dynamics simulation. The results showed that AD3BF2D ligand can be used as a good candidate for neuraminidase inhibitor to cope with influenza A virus subtype H1N1.
Singh S, Malhotra AG, Jha M, et al. Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies. Virusdisease, 2018, 29(4): 461-467.
DOI:10.1007/s13337-018-0480-2
2.
Nasution MAF, Toepak EP, Alkaff AH, et al. Flexible docking-based molecular dynamics simulation of natural product compounds and Ebola virus Nucleocapsid (EBOV NP): a computational approach to discover new drug for combating Ebola. BMC Bioinformatics, 2018, 19(Suppl 14): 419.
DOI:10.1186/s12859-018-2387-8
3.
Tambunan US, Zahroh H, Parikesit AA, et al. Screening Analogs of β-OG Pocket Binder as Fusion Inhibitor of Dengue Virus 2. Drug Target Insights, 2015, 9: 33-49.
DOI:10.4137/DTI.S31566